Drug
fosbretabulin
fosbretabulin is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
3
60%
Ph phase_1
2
40%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
terminated240%
completed360%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_1
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
NCT02055690
terminatedphase_1
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
NCT03014297
completedphase_2
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
NCT02279602
completedphase_2
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
NCT00653939
completedphase_2
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT01023295
Clinical Trials (5)
Showing 5 of 5 trials
NCT02055690Phase 1
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
NCT03014297Phase 1
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
NCT02279602Phase 2
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
NCT00653939Phase 2
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
NCT01023295Phase 2
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5